Ignite Creation Date:
2025-12-24 @ 11:15 PM
Ignite Modification Date:
2025-12-25 @ 8:52 PM
Study NCT ID:
NCT06024356
Status:
UNKNOWN
Last Update Posted:
2023-09-06
First Post:
2023-08-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015179', 'term': 'Colorectal Neoplasms'}], 'ancestors': [{'id': 'D007414', 'term': 'Intestinal Neoplasms'}, {'id': 'D005770', 'term': 'Gastrointestinal Neoplasms'}, {'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D003108', 'term': 'Colonic Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}, {'id': 'D012002', 'term': 'Rectal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077596', 'term': 'Thymalfasin'}], 'ancestors': [{'id': 'D013947', 'term': 'Thymosin'}, {'id': 'D013951', 'term': 'Thymus Hormones'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D036361', 'term': 'Peptide Hormones'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D011506', 'term': 'Proteins'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Pathology Paraffin Sections （Pre-NCRT and Post-NCRT）'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'RETROSPECTIVE', 'observationalModel': 'CASE_CONTROL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 26}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2023-09-20', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-09', 'completionDateStruct': {'date': '2024-03-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-09-05', 'studyFirstSubmitDate': '2023-08-08', 'studyFirstSubmitQcDate': '2023-09-05', 'lastUpdatePostDateStruct': {'date': '2023-09-06', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-09-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'The expression of CD86', 'timeFrame': '1 year', 'description': 'The density, H-score of each marker in paraffin-embedded tissue sections detected by mIHC'}, {'measure': 'The expression of CD163', 'timeFrame': '1 year', 'description': 'The density, H-score of each marker in paraffin-embedded tissue sections detected by mIHC'}, {'measure': 'The expression of CD4+', 'timeFrame': '1 year', 'description': 'The density, H-score of each marker in paraffin-embedded tissue sections detected by mIHC'}, {'measure': 'The expression of CD8+', 'timeFrame': '1 year', 'description': 'The density, H-score of each marker in paraffin-embedded tissue sections detected by mIHC'}, {'measure': 'The expression of PD-1', 'timeFrame': '1 year', 'description': 'The density, H-score of each marker in paraffin-embedded tissue sections detected by mIHC'}], 'primaryOutcomes': [{'measure': 'pathologic complete response', 'timeFrame': '1 year', 'description': 'All the enrolled patients will receive total mesorectal excision (TME) 7-9 weeks after the end of long course radiotherapy. The rectal specimens will be evaluated by the pathologists who are experienced on the rectal cancer diagnosis according to the 1997 Dworak grading system. The rectal cancer will be classified into 5 grades. Grade 0-3 will be considered as non-pCR while grade 4 represent pCR.'}], 'secondaryOutcomes': [{'measure': 'neoadjuvant rectal (NAR) score', 'timeFrame': '1 year', 'description': 'The neoadjuvant rectal (NAR) score is a promising indicator of survival after preoperative chemoradiotherapy for rectal cancer. The NAR score was calculated according to the following formula: NAR score = \\[5pN - 3(cT - pT) + 12\\]2⁄9.61.\n\n(clinical tumor (cT) stage, pathologic tumor (pT) stage, pathologic nodal (pN) stage)'}, {'measure': 'tumor regression grade（TRG）', 'timeFrame': '1 year', 'description': 'AJCC 8th TRG classification. TRG 0: No viable cancer cells left in the specimen; complete regression.\n\nTRG 1: Minimal residual cancer cells present; extensive regression with a minimal number of tumor cells.\n\nTRG 2: Moderate residual cancer cells present; substantial regression with a significant number of tumor cells.\n\nTRG 3: Minimal or no regression; no significant tumor cell response to treatment; majority of tumor still present.'}, {'measure': 'objective response rate (ORR)', 'timeFrame': '1 year', 'description': 'ORR is evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The ORR rate is the sum of complete response (CR) and partial response (PR)'}, {'measure': 'R0 resection rate', 'timeFrame': '1 year', 'description': 'During the surgical process, the surgeon will evaluate the level of cancer resection. It will be classified as R0, R1, R2 resection. Therefore, we can calculate R0 resection rate.'}, {'measure': 'anal preservation rate', 'timeFrame': '1 year', 'description': 'the surgeon will decide whether the anal can be preserved on the basis of the rectal cancer and intraoperative situation. anal preservation rate is the percentage of patients who achieve anal preservation.'}, {'measure': 'disease free survival (DFS)', 'timeFrame': '3 year', 'description': 'During the 3-year follow-up, the percentage of the patients who is disease free.'}, {'measure': 'local recurrence free survival', 'timeFrame': '3 year', 'description': 'During the 3-year follow-up, the percentage of local recurrence.'}, {'measure': 'overall survival (OS)', 'timeFrame': '3 year', 'description': 'During the 3-year follow-up, the percentage of the patients who is sill survival at the end of follow-up.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Colorectal Neoplasms', 'Programmed Cell Death 1 Receptor', 'Thymalfasin', 'Neoadjuvant Therapy'], 'conditions': ['Colorectal Neoplasms']}, 'descriptionModule': {'briefSummary': 'It is a single-center, retrospective, controlled study to investigate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer.', 'detailedDescription': 'Study Purpose\n\n1. To evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer.\n2. To explore the effects of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin on the immune microenvironment of locally advanced mid-low rectal cancer.\n\nStudy Design: A single-center, retrospective, controlled study Subjects were divided into two groups according to whether or not they received thymalfasin: group 1 was treated with neoadjuvant chemoradiotherapy combined with PD-1 inhibitor, and group 2 was treated with neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin.\n\nSubjects received long course radiotherapy (50 Gy/25f, 2 Gy/f, 5 days/week) for the first 5 weeks and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day 8) for the first 9 weeks. After that, patients rested for two weeks (week 10-11)。6-8 weeks after the end of radiotherapy, patients underwent TME surgery (12-14 weeks). Thymalfasin was started on the first day of neoadjuvant chemoradiotherapy, 1.6 mg subcutaneously twice a week until the end of the last neoadjuvant treatment.\n\nEnrollment: 26 participants, 13 in each group Study Population: locally advanced mid-low rectal cancer Primary Endpoint: pathologic complete response（pCR） Exploratory endpoint: Paraffin specimens were collected from biopsies before neoadjuvant therapy and after surgery in patients meeting the inclusion criteria. The expression of CD86, CD163, CD4+T，CD8+T，PD-1 were detected.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'locally advanced mid-low rectal cancer', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients with rectal adenocarcinoma must satisfied all the following conditions:\n\n 1. Stage II/III LARC (cT1-4aN0-2M0);\n 2. Tumor distal location≤10 cm from anal verge (MRI diagnosed);\n* Patients regardless of gender with aged≥18 years\n* ECOG score of 0 or 1\n* Physical and viscera function of patients can withstand major abdominal surgery\n\nExclusion Criteria:\n\n* Current or previous active malignancy other than rectal cancer；\n* Patients underwent major surgery within 4 weeks prior to neoadjuvant therapy；\n* Patients have any condition affects the absorption of capecitabine through gastrointestinal tract；\n* Patients have severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases;\n* Patients with severe concomitant diseases with estimated survival≤5 years；\n* Patients with present or previous moderate or severe liver and kidney damage；\n* Patients preparing for or previously received organ or bone marrow transplant；\n* Patients who have received immunosuppressive or systemic hormone therapy within 1 month prior to the start of neoadjuvant therapy；\n* Patients with congenital or acquired immune deficiency (such as HIV infection)；\n* Pregnant or lactating women.'}, 'identificationModule': {'nctId': 'NCT06024356', 'briefTitle': 'Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer', 'organization': {'class': 'OTHER', 'fullName': 'Beijing Friendship Hospital'}, 'officialTitle': 'Efficacy and Safety of Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer: a Single-center, Retrospective, Controlled Study', 'orgStudyIdInfo': {'id': 'BFH-TTNCRT'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Experimental', 'description': 'long course radiotherapy (50 Gy/25f, 2 Gy/f, 5 days/week) for the first 5 weeks and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day 8) for the first 9 weeks. After that, patients rested for two weeks (week 10-11)。6-8 weeks after the end of radiotherapy, patients underwent TME surgery (12-14 weeks). Thymalfasin was started on the first day of neoadjuvant chemoradiotherapy, 1.6 mg subcutaneously twice a week until the end of the last neoadjuvant treatment.', 'interventionNames': ['Drug: Thymalfasin']}, {'label': 'Control', 'description': 'long course radiotherapy (50 Gy/25f, 2 Gy/f, 5 days/week) for the first 5 weeks and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day 8) for the first 9 weeks. After that, patients rested for two weeks (week 10-11)。6-8 weeks after the end of radiotherapy, patients underwent TME surgery (12-14 weeks).'}], 'interventions': [{'name': 'Thymalfasin', 'type': 'DRUG', 'description': 'Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases.', 'armGroupLabels': ['Experimental']}]}, 'contactsLocationsModule': {'locations': [{'zip': '100050', 'city': 'Beijing', 'state': 'Xicheng Dis', 'country': 'China', 'facility': 'Beijing Friendship Hospital, Capital medical University', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}]}, 'ipdSharingStatementModule': {'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR', 'ANALYTIC_CODE'], 'timeFrame': '2025.5-', 'ipdSharing': 'YES', 'accessCriteria': 'via reasonable email requests'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Beijing Friendship Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'professor', 'investigatorFullName': 'Zhongtao Zhang', 'investigatorAffiliation': 'Beijing Friendship Hospital'}}}}